RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Longer-acting preexposure prophylaxis product and delivery preferences among transgender women in the United States
A discrete choice experiment
Roberts, S. T., Browne, E. N., Moore, E., Mungo, J., Mancuso, N., Diaz, M., & Minnis, A. M. (2025). Longer-acting preexposure prophylaxis product and delivery preferences among transgender women in the United States: A discrete choice experiment. AIDS, 39(14), 2140-2142. https://doi.org/10.1097/QAD.0000000000004280
An online discrete choice experiment elicited preferences for longer-acting preexposure prophylaxis (LA-PrEP) product and delivery characteristics among 90 transgender women in the United States. Over 10 questions, respondents chose between two hypothetical LA-PrEP options defined by product type, side effects, clinic type, appointment duration, and cost; or neither option (their current HIV prevention method). An LA-PrEP method was chosen over the current HIV prevention option in 94% of questions. Only cost significantly influenced LA-PrEP choice.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.